Injectable Hematology Growth Factors - Products, Therapeutics, Markets, &Forecasts

The "Injectable Hematology Growth Factors" is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for therapeutic biological drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Engineered Therapeutics for Refractory Conditions

Several recombinant hematologic growth factors or agonists for their receptors have been produced that are useful in treating anemia, neutropenia and thrombocytopenia, particularly in patients with end stage renal disease or aplastic anemia or who have received cancer chemotherapy or a hematopoietic cell transplant.

The shift in as-supplied packaging from single and multi-use vials to prefilled injection devices will accelerate over the next five years as drug developers move to empower an increasing number of chronically ill patients. The powerful physiological effects of antibodies, hormones and other biological drugs also increase the need for safety and compliance.

Report Value Matrix

What You Will Learn:

• What are the factors that define the market for injectable hematology growth factors?
• What are the major factors driving product development strategies within biologicals drug development organizations?
• How does the availability of patient support resources influence prescribing decisions for hematology growth factor drugs?
• How important are drug developer-formulation technologist relationships in therapeutic market segments?
• What is the current state of the global biologicals development and manufacturing ecosystem?
• What are the significant economic, technology, and regulatory factors affecting the selection criteria for growth factor therapeutics?